📊 IVF Key Takeaways
Is INVO Fertility, Inc. (IVF) a Good Investment?
INVO Fertility is in severe financial distress with negative profitability across all margins, critical liquidity crisis (current ratio of 0.12x), and substantial cash burn exceeding $7M annually. The company is losing $481.80 for every dollar of revenue generated, indicating fundamental business model challenges that cannot be attributed to early-stage development.
INVO Fertility's fundamentals are extremely weak, with flat revenue, very poor gross profitability, and operating losses that exceed annual sales. The balance sheet shows severe near-term liquidity stress, and the company's cash burn is far too high relative to its cash position, making financing risk and dilution risk major concerns.
Why Buy INVO Fertility, Inc. Stock? IVF Key Strengths
- Debt/Equity ratio of 0.34x indicates relatively moderate leverage
- Minimal capital expenditure suggests controlled cash outflow in non-operating areas
- Presence in surgical medical instruments sector provides potential market opportunity
- Revenue was roughly stable year over year, indicating the business has at least maintained its current scale
- Debt levels are not the primary balance-sheet problem, with debt/equity of 0.34x
- Stockholders' equity remains positive at $5.85M, so the company is not yet balance-sheet insolvent
IVF Stock Risks: INVO Fertility, Inc. Investment Risks
- Critical liquidity crisis with current ratio of 0.12x and only $355.9K cash against $13.0M liabilities
- Catastrophic profitability: -481.8% net margin and -110.8% operating margin indicating unsustainable business model
- Severe cash burn with operating cash flow of -$7.0M and free cash flow of -$7.1M threatening near-term solvency
- Revenue of only $5.3M with negative growth (-0.4% YoY) and minimal gross margin of 5.2%
- Net loss of $25.3M substantially exceeds annual revenue by 477%, indicating massive operating losses
- Gross margin of 5.2% and operating margin of -110.8% indicate an unsustainably weak business model at current scale
- Current ratio of 0.12x, quick ratio of 0.10x, and cash of just $355.89K point to severe liquidity risk
- Operating cash flow of -$7.04M and free cash flow of -$7.07M imply continued external funding needs
Key Metrics to Watch
- Cash position and burn rate trajectory to assess solvency timeline
- Operating cash flow and path to positive FCF generation
- Revenue growth and gross margin expansion to validate business model viability
- Liquidity ratios and ability to meet near-term obligations
- Gross margin and operating loss trend
- Cash balance relative to quarterly operating cash burn
INVO Fertility, Inc. (IVF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IVF Profit Margin, ROE & Profitability Analysis
IVF vs Healthcare Sector: How INVO Fertility, Inc. Compares
How INVO Fertility, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INVO Fertility, Inc. Stock Overvalued? IVF Valuation Analysis 2026
Based on fundamental analysis, INVO Fertility, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INVO Fertility, Inc. Balance Sheet: IVF Debt, Cash & Liquidity
IVF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: INVO Fertility, Inc.'s revenue has grown significantly by 58% over the 5-year period, indicating strong business expansion. The most recent EPS of $-67.37 indicates the company is currently unprofitable.
IVF Revenue Growth, EPS Growth & YoY Performance
IVF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $1.6M | -$1.6M | $-7.55 |
| Q3 2024 | $974.9K | -$1.2M | $-0.42 |
| Q2 2024 | $315.9K | -$1.6M | $-0.62 |
| Q1 2024 | $348.0K | -$1.6M | $-0.42 |
| Q3 2023 | $235.3K | -$1.2M | $-0.70 |
| Q2 2023 | $146.1K | -$2.2M | $-3.06 |
| Q1 2023 | $162.6K | -$2.6M | $-0.20 |
| Q3 2022 | $218.9K | -$2.2M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INVO Fertility, Inc. Dividends, Buybacks & Capital Allocation
IVF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for INVO Fertility, Inc. (CIK: 0001417926)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IVF
What is the AI rating for IVF?
INVO Fertility, Inc. (IVF) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IVF's key strengths?
Claude: Debt/Equity ratio of 0.34x indicates relatively moderate leverage. Minimal capital expenditure suggests controlled cash outflow in non-operating areas. ChatGPT: Revenue was roughly stable year over year, indicating the business has at least maintained its current scale. Debt levels are not the primary balance-sheet problem, with debt/equity of 0.34x.
What are the risks of investing in IVF?
Claude: Critical liquidity crisis with current ratio of 0.12x and only $355.9K cash against $13.0M liabilities. Catastrophic profitability: -481.8% net margin and -110.8% operating margin indicating unsustainable business model. ChatGPT: Gross margin of 5.2% and operating margin of -110.8% indicate an unsustainably weak business model at current scale. Current ratio of 0.12x, quick ratio of 0.10x, and cash of just $355.89K point to severe liquidity risk.
What is IVF's revenue and growth?
INVO Fertility, Inc. reported revenue of $5.3M.
Does IVF pay dividends?
INVO Fertility, Inc. does not currently pay dividends.
Where can I find IVF SEC filings?
Official SEC filings for INVO Fertility, Inc. (CIK: 0001417926) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IVF's EPS?
INVO Fertility, Inc. has a diluted EPS of $-17.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IVF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, INVO Fertility, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IVF stock overvalued or undervalued?
Valuation metrics for IVF: ROE of -433.1% (sector avg: 15%), net margin of -481.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IVF stock in 2026?
Our dual AI analysis gives INVO Fertility, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IVF's free cash flow?
INVO Fertility, Inc.'s operating cash flow is $-7.0M, with capital expenditures of $31.6K. FCF margin is -134.5%.
How does IVF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -481.8% (avg: 12%), ROE -433.1% (avg: 15%), current ratio 0.12 (avg: 2).